Anthropic Stock News: Greenshoe Used Up in 1 Day, What Next for ANT?

Anthropic's underwriters exercised their greenshoe option, buying 147 million additional shares at $83, increasing the total offering to 1.13 billion shares. The company raised $93.5 billion. ANT stock fell 8.5% to $88.91 on Friday, closing above the IPO price. The market cap is estimated at $1.19 trillion. The next catalyst may be Monday's trading session and potential early unlocking of 3.7 billion shares.

Original reporting
Published Nov 22, 2026, 6:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 22, 2026, 7:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Anthropic Stock News: Greenshoe Used Up in 1 Day, What Next for ANT? — source image
Decision brief

The 30-second read

$ANTNeutralLow
01

Why it matters

For ANT, the key trading question is whether full greenshoe use meaningfully changes near-term downside risk or whether it is largely mechanical and already priced after listing.

02

Market read

Traders may reassess ANT’s post-IPO downside cushion and stabilization narrative into the next session, but the article provides no confirmed causal link to the price drop.

03

What to watch

The article itself flags lack of confirmed causality for the Friday drop, so broader market/AI sentiment and general post-IPO profit-taking could be the dominant drivers rather than greenshoe mechanics.

Relevance 4/10Novelty 4/10Timing: ahead of Monday’s open after Friday’s close and after-hours move

Background

The article explains greenshoe (over-allotment) options and claims Anthropic’s underwriters exercised the full additional-share option at the offer price.

Company-level read

Ticker impact

$ANTNeutralMedium confidence
Context

Article says Anthropic underwriters bought the full 147M greenshoe shares at $83, and discusses whether that removes a cushion for ANT after a post-listing drop.

Expected impact

Likely near-term volatility around Monday’s open as traders reassess whether the greenshoe was a meaningful stabilizer versus a one-off listing mechanic.

Evidence & confidence

The piece provides specific greenshoe mechanics and ties them to a post-listing price slide, but it also admits no official source confirms the greenshoe as the cause of the move.

Market effects

Limited direct read-through to the broader AI/IPO market, but it can influence how traders price IPO stabilization mechanics for other high-profile listings.

Mostly US-focused via Nasdaq trading and IPO mechanics; crypto outlet framing suggests cross-asset risk appetite comparisons.

Low, as the story is specific to a single US-listed IPO and its underwriter over-allotment.

Counterpoint

The greenshoe being fully used may not be a bearish signal; it could simply mean demand was strong enough for underwriters to cover without needing additional market support.

Key entities

  • Anthropic

    Subject of the article, discussed via its IPO greenshoe exercise and subsequent ANT trading.

  • Goldman Sachs

    Named as a lead underwriter in the greenshoe/IPO deal mechanics.

  • Morgan Stanley

    Named as a lead underwriter and referenced in the tweet claim about full option use.

Related articles

$TSMMed

Export boom sends Q3 surplus soaring

Taiwan's Q3 current account surplus hit US$68.79B, driven by record exports of US$225.8B, largely due to AI-related demand. TSMC acquired a 0.03% stake in AI firm Anthropic for US$500M. Lam Research and SPIL announced expansions to support AI infrastructure. TSMC tightened restrictions on Chinese chip designers, limiting access to advanced tech.

$ANTMed

Anthropic Stock $88.91: 5 Analyst Targets Average $134

Anthropic's stock closed at $88.91 on Friday, down 8.5% from its debut. Analysts set targets averaging $134, with Melius Research highest at $155. Seaport Research rated it Neutral. The stock is 7.1% above its IPO price. Underwriters' research is expected after a 10-day quiet period.

$ANTHighAI 8/10

Anthropic rings the Nasdaq bell and then solves Riemann Hypothesis, what next now?

Anthropic (ANT) debuted on Nasdaq with a $1.5T market cap, briefly surpassing $2T before a selloff. The company aims to focus on institutional AI applications, particularly in medicine, and claims to have solved the Riemann Hypothesis. However, it faces challenges in justifying its valuation, with projected 2026 revenue of $45B falling short of the $600B needed for 20% returns on $1T AI investment. Sarvam, an Indian AI company, pivoted to offering inference services, sparking debate.

$ANTHighAI 8/10

How to Go 2x Long Anthropic (ANT): Leverage Shares by Themes Explains ANUU, the 2x Leveraged Anthropic ETF Launching Monday

Anthropic (ANT) priced its IPO at $83.00 per share, raising $81.3 billion, and began trading on Nasdaq at $111.50. Leverage Shares by Themes plans to launch ANUU, a 2X leveraged ETF tracking ANT, on November 23, 2026. The ETF is designed for active traders seeking daily 2X exposure to Anthropic's stock performance, with an expense ratio of 0.75%.

$ANTMed

[IT Times Weekly] Anthropic’s $93.5B Nasdaq Debut and Factory Humanoids Signal AI’s Industrial Era

Anthropic debuted on Nasdaq at $83/share, raising $93.5B (total $119.5B incl. private placement). Microsoft's AI security initiative flagged 9,791 vulnerabilities. Boston Dynamics' humanoid Atlas to trial in semiconductor fabs. Hyundai launched Avante with AI infotainment. Tether invested in SCRYPT for institutional crypto services. POSCO secured 3-year lithium supply deal with CATL.